A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS3797 in Healthy Subjects

Fujian Shengdi Pharmaceutical

Status and phase: Completed; Phase 1

Conditions: Skeletal Muscle Relaxation

Treatments: Drug: HRS3797

Study type: Interventional

Funder types: Industry

Identifiers

NCT05701826

HRS3797-103

Details and patient eligibility

About

This is a single-center, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of HRS3797 in Chinese adults. To evaluate the effect of IV infusion duration on the safety, tolerability, pharmacokinetics and pharmacodynamics of HRS3797. To explore the ED95 dosage of HRS3797 in Chinese adults.

Enrollment: 35 patients

Sex: All

Ages: 18 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Healthy male and female subjects aged 18 to 45 years;
2. Conform to the ASA I Physical Status Classification;
3. Male subjects weighed ≥ 50kg, female subjects weighed ≥ 45kg, and body mass index (BMI) was in the range of 19.0~26.0 kg/m2 (inclusive);
4. No pregnancy plan for the next 3 months and voluntary use of highly effective contraception during the trial;
5. Able and willing to provide a written informed consent.

Exclusion criteria

1. Subjects with any clinically serious disease, such as circulatory, endocrine, nervous, digestive, respiratory, hematological, immunological, psychiatric, or metabolic abnormalities, that may affect the pharmacokinetic characteristics or safety evaluation of the investigational drug as determined by the investigator;
2. Subjects with neuromuscular disease;
3. Subjects with a history of anatomic airway abnormalities;
4. Subjects with any known allergy history or specific allergic diseases (e.g., allergic asthma, urticaria, eczema, etc.);
5. Subjects who underwent major surgery within 3 months prior to screening;
6. Subjects who underwent surgery that could significantly affect the pharmacokinetic characteristics or safety evaluation of the investigational drug, or who planned to undergo surgery during the study period;
7. Subjects who received antihistamines or antidepressants within 3 months prior to screening;
8. Subjects who used any drug that inhibits or induces liver metabolism of drugs (e.g., inducers - barbiturates, carbamazepine, phenytoin, glucocorticoids, omeprazole; Inhibitors - SSRI antidepressants, cimetidine, diltiazem, macrolides, nitroimidazoles, sedatives and hypnotics, verapamil, fluoroquinolones, antihistamines) within 30 days prior to administration;
9. Subjects who had used any medication within 14 days prior to administration;
10. Subjects who took other investigational drugs or used investigational devices within 3 months prior to the screening, or who planned to participate in other clinical trials during the study period;
11. Subjects who donated blood or suffered massive blood loss of >= 400 mL (except for physiological blood loss in women), received blood transfusions or used blood products within 3 months prior to the study, or planned to donate blood during the study period or within 1 month after finishing the study;
12. Subjects who smoked more than 5 cigarettes per day on average within 3 months prior to the study, or who could not quit smoking during the study period;
13. Subjects had a history of alcohol abuse within 3 months prior to the study, i.e., an average of more than 14 units of alcohol per week;
14. Subjects who consumed excessive amounts of tea, coffee, and caffeinated beverages within 3 months prior to the study;
15. Subjects who consumed special diet (e.g., grapefruit, grapefruit juice or food/drink containing grapefruit juice, chocolate, tobacco, alcohol, caffeine, etc.) within 48 hours before administration;
16. Subjects who have special requirements for diet and cannot comply with a unified diet;
17. The results of various examinations during the screening period were judged by the research doctor to be clinically significant abnormal;
18. Subjects who have one or more positive test results for hepatitis B virus surface antigen, hepatitis C virus antibody, human immunodeficiency virus antibody, and Treponema pallidum antibody;
19. Women who are pregnant or have a positive pregnancy test, or during breast-feeding;
20. Subjects with positive alcohol expiratory test results;
21. Subjects with positive smoking test results;
22. Not suitable to be included in the study for other reasons as considered by investigators.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

35 participants in 6 patient groups

Treatment group A1

Experimental group

Description:

HRS3797 for injection

Treatment:

Drug: HRS3797

Drug: HRS3797

Drug: HRS3797

Treatment group A2

Experimental group

Description:

HRS3797 for injection

Treatment:

Drug: HRS3797

Drug: HRS3797

Drug: HRS3797

Treatment group B1

Experimental group

Description:

HRS3797 for injection

Treatment:

Drug: HRS3797

Drug: HRS3797

Drug: HRS3797

Treatment group B2

Experimental group

Description:

HRS3797 for injection

Treatment:

Drug: HRS3797

Drug: HRS3797

Drug: HRS3797

Treatment group C1

Experimental group

Description:

HRS3797 for injection

Treatment:

Drug: HRS3797

Drug: HRS3797

Drug: HRS3797

Treatment group C2

Experimental group

Description:

HRS3797 for injection

Treatment:

Drug: HRS3797

Drug: HRS3797

Drug: HRS3797